|
|
Retail pharmacy sales data for:
- USA
- Japan (includes
hospital pharmacy sales)
- Germany
- France
- Italy
- Brazil
- UK
- Spain
- Canada
- South Korea
Other notes:
General Method of Data Collection
IMS' pharmaceutical audits
for individual countries serve as the main source of comparative
sales data on the pharmaceutical industry. The audits are
continuous, periodic market surveys based on statistically
representative samples, the data from which provide regional
and national estimates. In the major countries, the pharmaceutical
audits incorporate transaction data from wholesalers giving
rise to a near-census of the retail market.
Each country audit records the data according to local requirements.
Therefore the way data is collected and held will vary from
country to country. In the European countries and America,
the majority of pharmaceuticals are dispensed or sold mainly
through retail pharmacies and drug stores. Thus sampling at
the retail pharmacy level in such countries will represent
a major proportion of the total market. Consequently, most
of the IMS audits are sampled through retail pharmacies. There
are some exceptions, for example Japan.
The audits provide a comprehensive record of purchases of
pharmaceuticals in each country. A number of retail pharmacies
and wholesalers are chosen for sampling (sample size) and
sales data is collected by IMS on a regular basis. This data
is then projected to estimate sales for the total number of
retail pharmacies in a country (this is referred to as the
universe). With some variation in each country, the sales
estimates shown represent direct and indirect purchases by
retail pharmacies from pharmaceutical wholesalers and manufacturers.
It should be noted that, whilst IMS data is the most comprehensive
source available to monitor sales through their retail channels,
some products are more widely distributed and used in a hospital
or clinic environment (for example oncology, diagnostic or
specialist anti-infective treatments). For such products,
IMS retailer-based audits do not provide comprehensive coverage,
and supplementary data sources will be required to project
these data to a total universe for these specialist products.
DATA VALUES AND DEFINITIONS
SALES VALUES
The dollar values in this report represent local currency
sales converted into US dollars on a quarterly basis, using
the prevailing average exchange rate for the quarter.
Sales values are standardised at EX-MANUFACTURER level. In
many countries, including USA, Canada, Japan and throughout
Latin America, these are estimated weighted average factors,
which take into account varying margins and the direct/indirect
sales mix. As market conditions change the conversion factors
are updated by the local IMS offices. Changes in factors are
not retroactively applied to historic data.
CORPORATE AFFILIATIONS
The corporate entity label
allows you to pinpoint the sales of any pharmaceutical corporation.
Any alterations in corporate affiliation are implemented retroactively.
Hence, the historic sales of a newly acquired subsidiary are
attributed to the new parent company for all the time periods.
E.G. Roche acquired a 65% stake in Genentech in 1990. Hence,
65% of Genetech's sales are attributed to Roche and 35% to
Genentech.
The treatment of joint-ventures here is that any percentage
ownership (eg 80:20, 70:30, 48:52, 50:50) is reflected in
the sales of the owning corporation. Where a company is owned
by two or more corporate groups, that company's sales are
apportioned to each of the owning corporations according to
their percentage ownership.
ANATOMICAL THERAPEUTIC CLASSIFICATION
(ATC)
The Anatomical Therapeutic
Classification, by which products are grouped according to
the part of the body they are used to treat, is now used in
IMS audits throughout the world, except in North America.
The Anatomical Therapeutic Classification of defined and maintained
by EPhMRA
|
